- 30748-47-12-Amino-4-methyl-5-acetylthiazole
- 307496-23-73-Pyridineethanamine,hydrobromide (1:2)
- 307496-25-94,7-Methano-1H-indene,3,7-diethyl-3a,4,7,7a-tetrahydro-
- 307496-32-8Zinc,bromo[(2,5-difluorophenyl)methyl]-
- 30751-05-4Benzamide,3,4,5-trimethoxy-N-3-piperidinyl-
- 307510-92-5Benzoic acid,4-[[4-oxo-2-thioxo-3-[3-(trifluoromethyl)phenyl]-5-thiazolidinylidene]methyl]-
- 307511-65-53-Thiophenecarboxylicacid, 2-amino-4-(3,4-dimethylphenyl)-, ethyl ester
- 307511-84-83-Thiophenecarboxylicacid, 2-amino-4-[4-(1,1-dimethylethyl)phenyl]-, ethyl ester
- 307512-22-7[1]Benzothieno[2,3-d]pyrimidin-4(1H)-one,2,3,5,6,7,8-hexahydro-7-methyl-3-(2-propen-1-yl)-2-thioxo-
- 307512-33-0Thieno[2,3-d]pyrimidine-4(3H)-thione,5,6-dimethyl-
Hot Products
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
- 7631-86-9Silicon dioxide
- 302-79-4Tretinoin
- 77-92-9Citric acid
|
Basic Information |
|
Post buying leads |
|
Suppliers |
| Name |
Feprazone |
EINECS | 250-324-3 |
| CAS No. | 30748-29-9 | Density | 1.175 g/cm3 |
| PSA | 40.62000 | LogP | 4.08390 |
| Solubility | N/A | Melting Point |
156.5° (ethanol) |
| Formula | C20H20N2O2 | Boiling Point | 437.197 °C at 760 mmHg |
| Molecular Weight | 320.391 | Flash Point | 178.698 °C |
| Transport Information | N/A | Appearance | N/A |
| Safety | Risk Codes | N/A | |
| Molecular Structure |
|
Hazard Symbols | N/A |
| Synonyms |
4-(2-Isopentenyl)-1,2-diphenyl-3,5-pyrazolidinedione;4-(3-Methyl-2-butenyl)-1,2-diphenyl-3,5-pyrazolidinedione;4-Prenyl-1,2-diphenyl-3,5-dioxopyrazolidine;4-Prenyl-1,2-diphenyl-3,5-pyrazolidinedione;Analud;DA 2370;Methrazone;Metrazone;Phenylprenazone;Pheprazone;Prenazone;Zepelin; |
Feprazone Specification
The 4-Phenyl-1,2-diphenyl-3,5-pyrazolidine-dione with the cas number 30748-29-9, is also called (1) 1,2-Diphenyl-4-(3-methyl-2-butenyl)-3,5-pyrazolidinedione; (2) 3,5-Pyrazolidinedione, 4-(3-methyl-2-butenyl)-1,2-diphenyl- ; (3) 4-(2-Isopentenyl)-1,2-diphenyl-3,5-pyrazolidinedione ; (4) 4-(3-Methyl-2-butenyl)-1,2-diphenyl-3,5-pyrazolidinedione ; (5) 4-(beta-Isoamylenyl)-1,2-diphenyl-3,5-pyrazolidinedione ; (6) 4-Prenyl-1,2-diphenyl-3,5-dioxopyrazolidine ; (7) 4-Prenyl-1,2-diphenyl-3,5-pyrazolidinedione ; (8) Analud ; (9) Fenilprenazone ; (10) Feprazona ; (11) Feprazona [INN-Spanish] ; (12) Feprazone ; (13) Feprazonum ; (14) Feprazonum [INN-Latin] ; (15) Methrazone ; (16) Phenylprenazone ; (17) Pheprazone ; (18) Prenazone ; (19) UNII-7BVX6J0CGR ; (20) Zepelin
Properties of 4-Phenyl-1,2-diphenyl-3,5-pyrazolidine-dione are: (1)ACD/BCF (pH 5.5): 163.78 ; (2)ACD/BCF (pH 7.4): 7.64 ; (3)ACD/KOC (pH 5.5): 1215.59 ; (4)ACD/KOC (pH 7.4): 56.68 ; (5)#H bond acceptors: 4 ; (6)#H bond donors: 0 ; (7)#Freely Rotating Bonds: 4 ; (8)Polar Surface Area: 40.62Å2 ; (9)Index of Refraction: 1.599 ; (10)Molar Refractivity: 93.24 cm3 ; (11)Molar Volume: 272.7 cm3 ; (12)Polarizability: 36.96× 10-24cm3 ; (13)Surface Tension: 46.8 dyne/cm ; (14)Density: 1.174 g/cm3 ; (15)Flash Point: 178.7 °C ; (16)Enthalpy of Vaporization: 69.38 kJ/mol ; (17)Boiling Point: 437.2 °C at 760 mmHg ; (18)Vapour Pressure: 7.62E-08 mmHg at 25°C
The 4-Phenyl-1,2-diphenyl-3,5-pyrazolidine-dione is applicable for treat with rheumatoid arthritis, rheumatoid arthritis, ankylosing arthritis, scapulohumeral periarthritis, thrombophlebitis, Myofibrositis, dentinum phlogosis, sciatica, etc. There may be side effect such as rash, drowsiness, edema, etc, and the one who with liver and kidney damage.
You can still convert the following datas into molecular structure :
1. SMILES: O=C2N(c1ccccc1)N(C(=O)C2C\C=C(/C)C)c3ccccc3
2. InChI: InChI=1/C20H20N2O2/c1-15(2)13-14-18-19(23)21(16-9-5-3-6-10-16)22(20(18)24)17-11-7-4-8-12-17/h3-13,18H,14H2,1-2H3
The 4-Phenyl-1,2-diphenyl-3,5-pyrazolidine-dione toxic data can be showed in the following sheet.
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LD50 | oral | > 2gm/kg (2000mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) GASTROINTESTINAL: ULCERATION OR BLEEDING FROM STOMACH | Yakkyoku. Pharmacy. Vol. 33, Pg. 233, 1982. |
| mouse | LD50 | intraperitoneal | 270mg/kg (270mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 10, Pg. 133, 1979. |
| mouse | LD50 | intravenous | 180mg/kg (180mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 22, Pg. 196, 1972. | |
| mouse | LD50 | oral | 1067mg/kg (1067mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Arzneimittel-Forschung. Drug Research. Vol. 22, Pg. 196, 1972. |
| mouse | LDLo | subcutaneous | 374mg/kg (374mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 10, Pg. 133, 1979. |
| rat | LD50 | intraperitoneal | 362mg/kg (362mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 10, Pg. 133, 1979. |
| rat | LD50 | oral | 1343mg/kg (1343mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 10, Pg. 133, 1979. |
| rat | LD50 | subcutaneous | 386mg/kg (386mg/kg) | Yaoxue Tongbao. Bulletin of Pharmacology. Vol. 20, Pg. 267, 1985. |
What can I do for you?
Get Best Price
